Main news

Dear colleagues!
Dear colleagues! I welcome you on behalf of the Organizing Committee of the XI International Forum for Cardiology and Internal Medicine, which will be held from March 22 to 24, 2022 in Moscow.


Polypill Shows LDL-Lowering Advantage in High-risk Primary Prevention Patients: VULCANO
Polypill Shows LDL-Lowering Advantage in High-risk Primary Prevention Patients: VULCANO Key Takeaways The CNIC (Centro Nacional de Investigaciones Cardiovasculares) polypill contains acetylsalicylic acid (100 mg), atorvastatin (30 mg or 40 mg), and ramipril (2.5 mg, 5 mg, or 10 mg), and is the only polypill for cardiovascular disease (CVD) currently marketed in European countries.


Editorial Activity

cardiology book

Current Overview on Hypercoagulability in COVID-19
Current Overview on Hypercoagulability in COVID-19 The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has brought many unique pathologies, such as coagulopathy, prompting a desperate need for effective management. COVID-19-associated coagulopathy (CAC) can cause various thromboembolic complications, especially in critically ill patients.


ESC/EACTS to Review Left Main Revascularization Guidance Patrice Wendling
ESC/EACTS to Review Left Main Revascularization Guidance Patrice Wendling The European Society of Cardiology and European Association for Cardiothoracic Surgery (ESC/EACTS) have announced they will review their joint recommendations for left main coronary artery disease in light of emerging data.



World Heart Day
World Heart Day On World Heart Day, 29 September 2020, we’re asking the world to Use Heart to beat CVD ... for your loved ones, society and you.



Major Indexing Service Calls Out Cardiology Journals for Self-Citation
Major Indexing Service Calls Out Cardiology Journals for Self-Citation More than 70% of the citations in one journal were to other papers in that journal. Another published a single paper that cited nearly 200 other articles in the journal.


Novel Lipid Therapies: 5 Things to Know
Novel Lipid Therapies: 5 Things to Know The development of novel pharmacotherapies targeting low-density lipoprotein (LDL), lipoprotein a, and triglycerides (TG) to help prevent patients' risk of atherosclerotic cardiovascular disease (ASCVD) has accelerated during the past decade.


COVID-19 and cardiovascular diseases: main aspects
COVID-19 and cardiovascular diseases: main aspects Igor S. Yavelov MD, PhD, Professor of cardiology